What is BioSerenity?
Headquartered in Paris and Atlanta, BioSerenity operates at the vanguard of neurology, sleep medicine, and cardiology. By integrating artificial intelligence with real-world evidence, the company provides sophisticated diagnostic solutions that bridge the gap between clinical research and patient care. Their platform serves as a critical infrastructure for healthcare providers, university medical facilities, and Contract Research Organizations (CROs) across the United States, Europe, and the Caribbean. Through its unique HaaS model, BioSerenity is effectively digitizing patient monitoring and diagnostic workflows, positioning itself as a high-authority entity in the global health-tech ecosystem.
How much funding has BioSerenity raised?
BioSerenity has raised a total of $92.9M across 3 funding rounds:
Angel/Seed
$3.4M
Series A
$17.9M
Series B
$71.7M
Angel/Seed (2015): $3.4M with participation from IdInvest Partners and Kurma Partners
Series A (2017): $17.9M led by LBO France and Idinvest Partners
Series B (2019): $71.7M, investors not publicly disclosed
Key Investors in BioSerenity
LBO France
LBO France is a leading investment fund with over 30 years of expertise in private equity, venture capital, and listed securities, focusing on sustainable value creation in digital health and other innovative sectors.
Idinvest Partners
Idinvest Partners is a prominent mid-market private equity firm based in Paris that specializes in financing and supporting entrepreneurs throughout various stages of business development.
Kurma Partners
Kurma Partners is a specialized healthcare and biotechnology venture firm that transforms disruptive scientific discoveries into advanced medical solutions for severe diseases.
What's next for BioSerenity?
Following this major strategic investment, BioSerenity is well-positioned to scale its diagnostic footprint and deepen its integration within international clinical research networks. The company's roadmap likely involves the expansion of its AI-driven diagnostic suite and the enhancement of its IoMT infrastructure to meet the rising demand for remote patient monitoring. As the firm transitions from its Series B phase toward broader market penetration, stakeholders anticipate further advancements in real-world evidence generation, which will be instrumental in securing regulatory approvals and expanding its influence in the global medical technology market.
See full BioSerenity company page
